Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS

Plain-language summary

This open-label study examines the effect of Sulforaphane in premutation carriers who have fragile X-associated tremor/ataxia syndrome (FXTAS). It enrolled people diagnosed with FXTAS who carry an FMR1 gene premutation (55-200 CGG repeats). It was a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

University of California, Davis

Intervention

Sulforaphane

Start date

6/25/2021

Estimated completion

1/1/2023

Countries

United States

Related genes

Locations

• Sacramento, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of FXTAS
* Presence of a FMR1 premutation (55 to 200 CGG repeats)

Exclusion Criteria:

* Individuals with severe renal failure (GFR is \<60 ml/min/1.73 m\^2)
* Significant and current reported substance abuse
* Individuals with substance use disorder (meets 6 or more symptoms of substance use disorder criteria)
* Any subject on hospice or on home oxygen
* Individuals who are pregnant